Yushe Dang

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice
    Keith L Knutson
    University of Washington, Tumor Vaccine Group, Department of Oncology, Seattle, Washington, USA
    Cancer Res 64:1146-51. 2004
  2. ncbi request reprint Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming
    Yushe Dang
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109, USA
    Clin Cancer Res 13:1883-91. 2007
  3. pmc Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer
    Kyong Hwa Park
    Department of Internal Medicine, Division of Oncology Hematology, Korea University, Seoul, Korea
    Cancer Res 68:8400-9. 2008
  4. doi request reprint Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer
    Yushe Dang
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109, USA
    Ann N Y Acad Sci 1174:81-7. 2009
  5. pmc Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells
    Yushe Dang
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109, USA
    Clin Cancer Res 18:3122-31. 2012
  6. pmc Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer
    Mary L Disis
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98195 8050, USA
    J Clin Oncol 27:4685-92. 2009
  7. pmc Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells
    Hailing Lu
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 17:67-76. 2011
  8. pmc ELISpot for measuring human immune responses to vaccines
    Meredith Slota
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, 815 Mercer Street, University of Washington, Seattle, WA 98058, USA
    Expert Rev Vaccines 10:299-306. 2011
  9. ncbi request reprint IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice
    Keith L Knutson
    Department of Immunology, Mayo Clinic College of Medicine, 342C Guggenheim, 200 First Street SW, Rochester, MN 55905, USA
    J Immunol 177:84-91. 2006

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice
    Keith L Knutson
    University of Washington, Tumor Vaccine Group, Department of Oncology, Seattle, Washington, USA
    Cancer Res 64:1146-51. 2004
    ....
  2. ncbi request reprint Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming
    Yushe Dang
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109, USA
    Clin Cancer Res 13:1883-91. 2007
    ..In this study, we evaluated the feasibility of expanding HER-2/neu-specific T cells derived from peripheral blood ex vivo following in vivo priming with a HER-2/neu peptide vaccine...
  3. pmc Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer
    Kyong Hwa Park
    Department of Internal Medicine, Division of Oncology Hematology, Korea University, Seoul, Korea
    Cancer Res 68:8400-9. 2008
    ..This is the first report of IGFBP-2 as a human tumor antigen that may be a functional therapeutic target in breast cancer...
  4. doi request reprint Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer
    Yushe Dang
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109, USA
    Ann N Y Acad Sci 1174:81-7. 2009
    ..Most likely the clinical effectiveness of immune-based treatments will be predicted by panels of markers rather than single assays of a specific immune effector cell...
  5. pmc Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells
    Yushe Dang
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109, USA
    Clin Cancer Res 18:3122-31. 2012
    ....
  6. pmc Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer
    Mary L Disis
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98195 8050, USA
    J Clin Oncol 27:4685-92. 2009
    ....
  7. pmc Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells
    Hailing Lu
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 17:67-76. 2011
    ..The current study was undertaken to investigate the mechanism of the antitumor actions of PSK...
  8. pmc ELISpot for measuring human immune responses to vaccines
    Meredith Slota
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, 815 Mercer Street, University of Washington, Seattle, WA 98058, USA
    Expert Rev Vaccines 10:299-306. 2011
    ....
  9. ncbi request reprint IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice
    Keith L Knutson
    Department of Immunology, Mayo Clinic College of Medicine, 342C Guggenheim, 200 First Street SW, Rochester, MN 55905, USA
    J Immunol 177:84-91. 2006
    ....